<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14348">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310791</url>
  </required_header>
  <id_info>
    <org_study_id>Anorexia04</org_study_id>
    <secondary_id>RO1 HD043869</secondary_id>
    <nct_id>NCT00310791</nct_id>
  </id_info>
  <brief_title>Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa</brief_title>
  <official_title>Effects of Adrenal and Gonadal Hormone Replacement in Young Women With Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Boston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Boston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to gain new information on why young women with anorexia nervosa are
      predisposed to early bone loss and osteoporosis. Through a randomized treatment trial in
      which participants will receive either combined therapy with the adrenal hormone,
      dehydroepiandrosterone (DHEA) and estrogen replacement therapy or placebo, we will determine
      the effects of an 18-month treatment course on bone mass, circulating markers of bone
      turnover, and serum levels of a factor, insulin-like growth factor I (IGF-I). We are also
      studying if these therapies change bone structure to increase skeletal strength compared to
      placebo, as assessed through cross-sectional geometric analysis of our bone density data by
      dual-energy x-ray absorptiometry (DXA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Profound osteopenia is a frequent and often irreversible complication of anorexia nervosa
      (AN). Adolescents with AN often have a reduced peak bone mass and are at increased risk for
      early osteoporosis and fractures. These young women have subnormal serum levels of gonadal
      steroids and the adrenal androgen dehydroepiandrosterone (DHEA) that may be associated with
      their low bone mineral density (BMD). Low DHEA levels are accompanied by decreased levels of
      insulin-like growth factor I (IGF-I), estrogen, and testosterone. Previous data from our
      group indicate that oral DHEA therapy in young women with AN: increases lean body mass,
      serum levels of bone formation markers and insulin-like growth factor I (IGF-I), and
      decreases urinary markers of bone resorption. We also found that standard hormonal
      replacement therapy (HRT) significantly decreased bone resorption markers. Information on
      the effects of these therapies on bone strength and ultimate fracture risk is lacking.

      In this project, we will test the hypothesis that combined therapy with DHEA and
      estrogen/progestin will enhance bone mass in patients with AN through anabolic and
      antiosteolytic mechanisms. We will test the hypothesis that 18 months of DHEA + HRT will
      increase bone mineral density (BMD) and markers of bone formation, while decreasing bone
      resorption markers in these patients. The proposed study will examine whether restoring
      normal levels of DHEA and estrogen in these young women will increase bone mass during a
      critical period for bone accretion. The study will also examine whether DHEA's anabolic
      effects on bone are mediated through the skeletal IGF-I regulatory system. Using
      cross-sectional analyses of dual energy x-ray absorptiometry (DXA) data, we will also
      measure indices of bone structural geometry to determine if mechanical strength is
      compromised in these young women, and if strength is restored in response to combined
      anabolic/antiresorptive therapy.

      To gain new information on the mechanisms underlying bone loss and fracture risk in young
      women with AN, our research goals are:

      Specific Aim I: Through a randomized controlled trial, to measure the effects of an 18-month
      course of DHEA + HRT on bone mass, markers of bone turnover, and serum levels of IGF-I
      compared to placebo. Specific Aim II: To determine whether combined therapy with adrenal and
      gonadal steroid replacement changes bone structure to increase strength compared to placebo,
      as assessed through cross-sectional geometric analysis of DXA data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Areal Bone Density by DXA</measure>
    <time_frame>18-Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sugar pill); identical to treatment medication capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHEA + Hormone replacement therapy (estrogen/progestin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (&gt; 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormone replacement therapy (estrogen/progestin)</intervention_name>
    <description>Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)</description>
    <arm_group_label>DHEA + Hormone replacement therapy (estrogen/progestin)</arm_group_label>
    <other_name>Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)</other_name>
    <other_name>Premarin (conjugated estrogens)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Sugar Pill)</intervention_name>
    <description>Placebo (sugar pill)</description>
    <arm_group_label>Sugar Pill</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone (DHEA)</intervention_name>
    <description>50 mg tablet, 1 daily</description>
    <arm_group_label>DHEA + Hormone replacement therapy (estrogen/progestin)</arm_group_label>
    <other_name>Prasterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 15 - 30 years

          -  Anorexia nervosa by psychiatric criteria

          -  Amenorrhea for at least 3 months

        Exclusion Criteria:

          -  Receiving no medications known to affects bone metabolism

          -  No other chronic medical conditions
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine M. Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 27, 2012</lastchanged_date>
  <firstreceived_date>April 3, 2006</firstreceived_date>
  <firstreceived_results_date>June 22, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Boston</investigator_affiliation>
    <investigator_full_name>Catherine M. Gordon</investigator_full_name>
    <investigator_title>Catherine Gordon, MD, MSc</investigator_title>
  </responsible_party>
  <keyword>anorexia nervosa</keyword>
  <keyword>adolescents</keyword>
  <keyword>dual-energy x-ray absorptiometry</keyword>
  <keyword>dehydroepiandrosterone (DHEA)</keyword>
  <keyword>osteoporosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Active</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Active</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="21" spread="4"/>
                <measurement group_id="B2" value="24" spread="6"/>
                <measurement group_id="B3" value="22" spread="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="40"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Areal Bone Density by DXA</title>
        <time_frame>18-Months</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sugar Pill</description>
          </group>
          <group group_id="O2">
            <title>Active</title>
            <description>DHEA+HRT</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Areal Bone Density by DXA</title>
            <units>g/cm2</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" spread="0.10"/>
                  <measurement group_id="O2" value="0.89" spread="0.10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Active</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Catherine Gordon</name_or_title>
      <organization>Children's Hospital Boston</organization>
      <phone>401-444-4712</phone>
      <email>cgordon1@lifespan.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
